B7-H4 as an independent prognostic indicator of cancer patients: a meta-analysis

Zibo Meng; Feiyang Wang; Yushun Zhang; Shoukang Li; Heshui Wu

doi:10.18632/oncotarget.18566

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Meta-Analysis:

This article has been corrected. Correction in: Oncotarget. 2018; 9:13100.

B7-H4 as an independent prognostic indicator of cancer patients: a meta-analysis

Zibo Meng, Feiyang Wang, Yushun Zhang, Shoukang Li and Heshui Wu _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2017; 8:68825-68836. https://doi.org/10.18632/oncotarget.18566

Metrics: PDF 1906 views | HTML 2025 views | ?

Abstract

Zibo Meng1,*, Feiyang Wang1,*, Yushun Zhang1, Shoukang Li1 and Heshui Wu1

1Department of Pancreatic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China

*These authors contribute equally to this work

Correspondence to:

Heshui Wu, email: [email protected]

Keywords: B7-H4, cancer, prognosis, meta-analysis

Received: May 09, 2017 Accepted: June 11, 2017 Published: June 19, 2017

ABSTRACT

The expression of B7-H4 was observed in a variety of tumors, however the prognostic value in cancer was still controversial. Therefore, we conducted this meta-analysis to explore the potential role of B7-H4 in cancer prognostic prediction. Twenty-seven studies including 3771 patients were brought into the analysis according to the inclusion and exclusion criteria. The pooled results demonstrated that elevated B7-H4 predicted a poor OS (HR = 1.93, 95% CI 1.71-2.18, P < 0.001) and DFS (HR = 1.84, 95% CI 1.46-2.33, P < 0.001). Subgroup analysis showed that races, tumor types, sample sources, analysis types, sources of HR and sample sizes exhibited non-significant distinctions with OS (P_S = 0.878, P_S = 0.143, P_S = 0.613, P_S = 0.639, P_S = 0.48 and P_S = 0.528, respectively). PubMed, Embase and the Cochrane Library were searched up to April 7, 2017, to recognize the available studies for assessing the association between B7-H4 and cancer patients’ outcome. We extracted the hazard ratio (HR), relative ratio (RR), odds ratio (OR) with their 95% confidence interval (CI) for overall survival (OS) or disease-free survival (DFS) as the effect size (ES) for the analysis. This meta-analysis demonstrates high expression of B7-H4 is a negative correlation with the outcome of cancer patients.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 18566

Publication Alerts

Meta-Analysis:

B7-H4 as an independent prognostic indicator of cancer patients: a meta-analysis

Abstract